Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 6/20 | 0.33 |
| ▸ | JAK2 | O60674 | 5/20 | 0.33 |
| ▸ | JAK1 | P23458 | 3/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2787055 | 0.80 | PDPK1 (0.39) | GSK3B | |
| SCHEMBL4308970 | 0.78 | RIPK1 (0.31) | — | |
| Pyrrole SCHEMBL12467466 | 0.72 | PDPK1 (0.38) | — | |
| SCHEMBL1162652 | 0.69 | — | — | |
| SCHEMBL4102491 | 0.64 | KDM4E (0.48) | — | |
| SCHEMBL4112718 | 0.64 | P2RX7 (0.49) | — | |
| SCHEMBL7052922 | 0.63 | KDM4E (0.32) | — | |
| SCHEMBL10424836 | 0.62 | PDPK1 (0.38) | — | |
| SCHEMBL19463620 | 0.60 | PIM1 (0.43) | — | |
| SCHEMBL2351446 | 0.60 | ALOX5AP (0.35) | JAK3JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2586444-B1 | Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate control composition | MERCK SHARP & DOHME (US) | 2019-09-25 | — | — | EP | disclosed |
| EP-1904067-B2 | PHARMACEUTICAL FORMULATION OF CARBOXAMIDE HIV INTEGRASE INHIBITORS CONTAINING A RELEASE RATE CONTROLLING COMPOSITION | MERCK SHARP & DOHME (US) | 2017-10-11 | — | — | EP | disclosed |
| US-8852632-B2 | Pharmaceutical formulation containing a release rate controlling composition | MERCK SHARP & DOHME CORP. (US) | 2014-10-07 | — | — | US | disclosed |
| EP-1904067-B1 | PHARMACEUTICAL FORMULATION OF CARBOXAMIDE HIV INTEGRASE INHIBITORS CONTAINING A RELEASE RATE CONTROLLING COMPOSITION | MERCK SHARP & DOHME (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-2586444-A1 | Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate control composition | Merck Sharp & Dohme Corp. (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20090136570-A1 | Taste-Masked Tablets and Granules | UNIVERSITAT ZURICH (CH) | 2009-05-28 | — | — | US | disclosed |
| US-20090136570-A1 | Taste-Masked Tablets and Granules | UNIVERSITAT ZURICH (CH) | 2009-05-28 | — | — | US | disclosed |
| WO-2007087188-A8 | TASTE-MASKED TABLETS AND GRANULES | MERCK & CO INC (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20070292504-A1 | Pharmaceutical formulation containing a release rate controlling composition | MERCK SHARP & DOHME LLC | 2007-12-20 | — | — | US | disclosed |
| WO-2007087188-A3 | TASTE-MASKED TABLETS AND GRANULES | MERCK & CO INC (US) | 2007-12-13 | — | — | WO | disclosed |
| US-20070259894-A1 | Use of Atazanavir for Improving the Pharmacokinetics of Drugs Metabolized by Ugt1a1 | MERCK SHARP & DOHME CORP. | 2007-11-08 | — | — | US | disclosed |
| EP-1824957-A2 | USE OF ATAZANAVIR FOR IMPROVING THE PHARMACOKINETICS OF DRUGS METABOLIZED BY UGT1A1 | Merck & Co., Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| WO-2007087188-A2 | TASTE-MASKED TABLETS AND GRANULES | MERCK & CO., INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007087188-A2 | TASTE-MASKED TABLETS AND GRANULES | MERCK & CO., INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2006060731-A2 | USE OF ATAZANAVIR FOR IMPROVING THE PHARMACOKINETICS OF DRUGS METABOLIZED BY UGT1A1 | MERCK & CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259894-A1 | Use of Atazanavir for Improving the Pharmacokinetics of Drugs Metabolized by Ugt1a1 | UGT1A1, UGT1A3, UGT1A9 | JAK3 1443/4885JAK2 2603/4885JAK1 709/4885 |
| US-20090136570-A1 | Taste-Masked Tablets and Granules | TAS2R30, TAS2R40, TAS2R42 | JAK3 1323/4885JAK2 1684/4885JAK1 1142/4885 |
| US-20070292504-A1 | Pharmaceutical formulation containing a release rate controlling composition | REV1, POLR2H, POLR2E | JAK3 1157/4885JAK2 2153/4885JAK1 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.